Efficacy, Safety and Quality of Life in Patients Receiving Subcutaneous Igg Treatment: Experience in Bogotá, Colombia

Ortega-López, María Claudia; Garay, J. Garrós; Pinilla, Mónica León

doi:10.2217/imt-2018-0038

Cited by 4 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite prescribers playing a major role in IgRT modality choice, the finding that the SCIg cohort was associated with a better perceived effectiveness compared with the IVIg cohort may be, in part, attributed to the SCIg cohort (especially the SCIg naïve cohort) feeling more empowered. Self-infusing SCIg users play a more active role in their treatment compared with their IVIg counterparts, giving them the feeling of empowerment [41][42][43][44]. Indeed, patient preference assessments highlight the importance of continually offering patients information and a choice of IgRT infusion options [30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Mallick

Solomon²,

Bassett³

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Background Understanding the impact of different immunoglobulin (Ig) infusion methods (intravenous [IVIg] and subcutaneous [SCIg]) upon treatment experience can potentially facilitate optimization of patient outcomes. Here, the perspective of patients with primary and secondary immunodeficiency diseases (PID and SID, respectively) receiving IVIg and SCIg was evaluated, in terms of treatment satisfaction, accounting for treatment history, using Association des Patients Immunodéficients du Québec (APIQ) survey data. Methods The online APIQ survey (shared October 2020–March 2021) of patients with immunodeficiencies in Canada contained 101 questions on: Ig use, history, and detailed infusion characteristics; as well as structured patient-reported outcomes such as treatment satisfaction (via TSQM-9), symptom state (via PASS), general health perception (via GHP), and physical and mental function (via PROMIS). Adult respondents (≥ 18 years old) currently using Ig were compared by their current Ig infusion method (IVIg or SCIg cohort) overall, and in a sub-analysis, the IVIg cohort was compared with the SCIg cohort after stratification by respondents who started SCIg when naïve to Ig (‘SCIg naïve’) or with previous IVIg experience (‘SCIg switch’). Results In total, 54 respondents currently used IVIg and 242 used SCIg. The average duration per infusion of a weekly SCIg infusion was significantly shorter compared with the average duration of a 3–4 weekly IVIg infusion (p < 0.001). The SCIg cohort was associated with significantly higher scores for the TSQM-9 effectiveness domain compared with the IVIg cohort. The scores for TSQM-9 convenience and global satisfaction domains were similar in the two cohorts. The SCIg cohort was also associated with a significantly higher proportion of respondents who were in an acceptable symptom state and a lower proportion who reported very poor or poor perception of health compared with the IVIg cohort. Further, the SCIg naïve subgroup was associated with significantly higher TSQM-9 effectiveness and convenience domain scores compared with the IVIg cohort, while there was no significant difference between the SCIg switch subgroup and the IVIg cohort in terms of convenience. Conclusions A better understanding of how different IgRT administration methods impact treatment experience and satisfaction may assist with informed treatment decision making and ultimately further improvements in patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Mallick

Solomon²,

Bassett³

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

show abstract

Health-Related Quality of Life of Patients and Families with Primary Immunodeficiency in Malaysia: a Cross-Sectional Study

et al. 2023

View full text Add to dashboard Cite

Pharmacokinetic properties of Privigen^® in Japanese patients with primary immunodeficiency

Morio

Baheti

Tortorici

et al. 2019

Immunological Medicine

View full text Add to dashboard Cite

This prospective, Phase 3, open-label, study (EudraCT: 2016-001631-12) evaluated pharmacokinetic (PK) characteristics of 3-/4-weekly Privigen V R (IgPro10, CSL Behring, King of Prussia, PA, USA) in Japanese patients with PID. PK parameters including serum trough immunoglobulin (IgG) level before next infusion during the wash-in/wash-out phase (C trough), area under the concentration-time curve from time point zero to the last time point with quantifiable concentration (AUC 0-last), dose-adjusted AUC 0-last (dAUC), lowest and highest observed IgG levels (C min , C max), time to reach C max (T max), and total clearance (CL) were analyzed for both regimens of Privigen V R (dose: 138-554 mg/kg body weight). Ten patients were included in this analysis (3-/4-weekly: n ¼ 2/n ¼ 8). C trough levels achieved ranged 7.96-10.05 g/L. C max was observed approximately 1 h after the start of the infusion in both regimens. Mean (SD [not applicable for 3-weekly data]) PK parameters: C max , 16.60 and 14.20 (5.53) g/L; C min , 10.60 and 8.53 (3.89) g/L; AUC 0-last , 5971 and 6591 (2633) g Ã h/L; dAUC, 0.41 and 0.46 (0.19) g Ã h/L/ mg; CL, 2.53 and 2.53 (1.00) mL/h and median T max was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively. Privigen V R PK characteristics in Japanese patients were similar between dosing regimens and to previously-reported results in non-Japanese patients with PID.

show abstract

Efficacy, Safety and Quality of Life in Patients Receiving Subcutaneous Igg Treatment: Experience in Bogotá, Colombia

Abstract: Self-administration of SCIG provided effective protection, favorable tolerability and improved quality of life in patients with PIDs and autoimmune diseases from Colombia.

Cited by 4 publications

References 36 publications

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Health-Related Quality of Life of Patients and Families with Primary Immunodeficiency in Malaysia: a Cross-Sectional Study

Pharmacokinetic properties of Privigen^® in Japanese patients with primary immunodeficiency

Contact Info

Product

Resources

About

Efficacy, Safety and Quality of Life in Patients Receiving Subcutaneous Igg Treatment: Experience in Bogotá, Colombia

Abstract: Self-administration of SCIG provided effective protection, favorable tolerability and improved quality of life in patients with PIDs and autoimmune diseases from Colombia.

Cited by 4 publications

References 36 publications

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Health-Related Quality of Life of Patients and Families with Primary Immunodeficiency in Malaysia: a Cross-Sectional Study

Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency

Contact Info

Product

Resources

About

Pharmacokinetic properties of Privigen^® in Japanese patients with primary immunodeficiency